All In Biotech

Drug Trial Radar · NCT01020838

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

An Open-label, Non-randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) Imaging for Detection/Exclusion of Cerebral Beta-amyloid When Compared to Postmortem Histopathology

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

218

Actual

Start

Nov 2009

Primary completion

Sep 2011

Study completion Dec 2013

Sponsor

Lead sponsor
Lantheus Biosciences Ltd.Industry
Sponsor type
Industry
First posted
Nov 26, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the sensitivity and specificity of the visual assessment of tracer uptake in the Florbetaben PET images compared to histological verification of the presence or absence of cerebral β-amyloid in the respective histopathologic post mortem specimens as the standard of truth

Conditions

  • Alzheimer Disease

Interventions

  • Florbetaben (BAY94-9172)Drug

    Single intravenous injection 1-5ml, 300 MBq (+/- 20%)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity and Specificity of the Majority Read of Visual Assessment of Tracer Uptake Compared to Histological Verification of the Presence or Absence of Cerebral Beta-amyloid in Postmortem SpecimensTime frame: 90-110 minutes post injection (PET image acquisition)

Locations

19 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Sun City, Arizona

  • Site not named

    Stanford, California

  • Site not named

    Tampa, Florida

  • Site not named

    Teaneck, New Jersey

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Heidelberg, Victoria, Australia

  • Site not named

    Lille, France

  • Site not named

    Strasbourg, France

  • Site not named

    Jülich, North Rhine-Westphalia, Germany

  • Site not named

    Leipzig, Saxony, Germany

  • Site not named

    Toyohashi, Aichi-ken, Japan

  • Site not named

    Toyohashi, Aichi-ken, Japan

  • Site not named

    Toyohashi, Aichi-ken, Japan

  • Site not named

    Isesaki, Gunma, Japan

  • Site not named

    Hamamatsu, Shizuoka, Japan

  • Site not named

    tabashi City, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.